Abstract
Pseudomonas aeruginosa is considered as the most redoubtable pathogenic agent at cystic fibrosis patients. Its eradication is a priority to avoid the passage to chronic infection, the real turning point of the disease. For this, a wide therapeutic panel of intravenous antibiotics exists, and for some years, the research teams concentrate more and more on the inhaled way. The synthesis of the literature data presented herein focuses on both already experienced molecules (colistin and tobramycin), and on new therapeutics. This review aims at loosening advantages and inconveniences of each of these therapeutic options, while bringing to light the necessity of follow-up studies in order to prove the therapeutic interests of molecules in development.
© 2011 Société Française de Pharmacologie et de Thérapeutique.
MeSH terms
-
Administration, Inhalation
-
Aerosols
-
Amikacin / administration & dosage
-
Amikacin / adverse effects
-
Amikacin / therapeutic use
-
Anti-Infective Agents / administration & dosage*
-
Anti-Infective Agents / adverse effects
-
Anti-Infective Agents / therapeutic use*
-
Ciprofloxacin / administration & dosage
-
Ciprofloxacin / therapeutic use
-
Colistin / administration & dosage
-
Colistin / adverse effects
-
Colistin / therapeutic use
-
Cystic Fibrosis / complications*
-
Drug Therapy, Combination
-
Fluoroquinolones / administration & dosage
-
Fluoroquinolones / adverse effects
-
Fluoroquinolones / therapeutic use
-
Humans
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas Infections / etiology*
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / drug effects
-
Tobramycin / administration & dosage
-
Tobramycin / adverse effects
-
Tobramycin / therapeutic use
Substances
-
Aerosols
-
Anti-Infective Agents
-
Fluoroquinolones
-
Ciprofloxacin
-
Amikacin
-
Tobramycin
-
Colistin